Caris Life Sciences has introduced Caris MI Clarity™, an AI-powered prognostic test that assesses both early and late distant recurrence risks for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. The test uses AI to analyze routine pathology slides and clinical data, delivering results within three business days, much faster than traditional methods. This innovation helps doctors better personalize treatment by understanding how recurrence risk evolves over time, potentially improving patient outcomes and reducing overtreatment or undertreatment. The test's development involved extensive validation with national clinical trial data, marking a significant advancement in breast cancer risk assessment and management.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
